BIOLINERX     Print Page  Close Window

SEC filings
6-K
BIOLINERX LTD. filed this Form 6-K on 08/20/2015
Entire Document
 
8

 

BioLineRx Ltd.
APPENDIX TO CONDENSED CONSOLIDATED INTERIM CASH FLOW STATEMENTS
(UNAUDITED)

       
   
Six months ended June 30,
 
   
2014
   
2015
 
   
in USD thousands
 
             
Adjustments required to reflect net cash used in operating activities:
           
             
Income and expenses not involving cash flows:
           
Depreciation and amortization
    139       195  
Long-term prepaid expenses
    2       (8 )
Interest on restricted deposits
    1       -  
Interest and exchange rate differences on short-term deposits
    238       (49 )
Share-based compensation
    498       487  
Exchange differences on cash and cash equivalents
    (63 )     13  
Loss (gain) on adjustment of warrants to fair value
    (2,314 )     887  
Commitment fee paid by issuance of share capital
    303       -  
      (1,196 )     1,525  
                 
Changes in operating asset and liability items:
               
Increase in trade accounts receivable and
other receivables
    (71 )     (425 )
Increase (decrease) in accounts payable and accruals
    (284 )     876  
      (355 )     451  
      (1,551 )     1,976  
                 
Supplementary information on investing activities not
    involving cash flows:
               
    Property and equipment acquired on supplier trade credit
    -       512  
                 
Supplementary information on interest received in cash
    28       30  
 
9